PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents yoy growth below half of AVXL's 20877.14%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of AVXL's 20877.14%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
Below half of AVXL's 11206.01%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
101.21%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Below half of AVXL's 11206.01%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-44.89%
1.1-1.25x AVXL's -38.13%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Less than half of AVXL's -8.10%. David Dodd sees fewer expansions in other current obligations.
112.59%
Less than half of AVXL's -45.10%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Less than half of AVXL's -19.69%. David Dodd sees far fewer liability expansions relative to competitor.
-89.62%
Less than half of AVXL's 23.14%. David Dodd sees fewer share issuances vs. competitor.
-9.70%
1.25-1.5x AVXL's -7.82%. Bruce Berkowitz notes stronger reinvestment strategy.
98.99%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
100.73%
1.25-1.5x AVXL's 79.92%. Martin Whitman is wary of complicated equity expansions.
-358.06%
Below half AVXL's 30.68%. Michael Burry sees potential underperformance in building shareholder capital.
42.36%
Below half AVXL's 11206.01%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
Less than half of AVXL's -117.75%. David Dodd sees better deleveraging or stronger cash buildup than competitor.